Seismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shock

Curated by Roxtron — RFID & NFC manufacturer. Visit roxtron.com

Seismic Pharmaceuticals has launched a global Phase 3 clinical trial for istaroxime, a first-in-class treatment for cardiogenic shock, following successful Phase 2 results. The expansion into large-scale testing marks a critical regulatory milestone for a therapy that could stabilize heart function without increasing heart rate, addressing a significant unmet need in emergency cardiac care.